CalciMedica Q2 2026: Going Concern Warning as Cash Dwindles to $18.6M
CALC sits 43% above its 52-week low of $0.461 on light trading volume (0.1× avg).
Summary
CalciMedica's Q2 2026 10-Q discloses a going concern warning with only $18.6 million in cash, enough to fund operations into the second half of 2027. The company faces Nasdaq delisting and must raise substantial additional capital to continue development of its drug candidates.
Key Events · Earnings and Guidance · CALC
-
Going Concern Warning
Management states substantial doubt about the company's ability to continue as a going concern, with cash and cash equivalents of $18.6 million as of June 30, 2026, expected to fund operations only into the second half of 2027.
-
Financial Results
Net loss of $2.7 million for the six months ended June 30, 2026, included a $7.2 million non-cash gain from fair value adjustments of warrant and promissory note liabilities. Operating expenses were $9.6 million, down 27% year-over-year due to reduced clinical trial activity.
-
Nasdaq Delisting Risk
The company received notices from Nasdaq for non-compliance with the minimum market value of listed securities and minimum bid price requirements. It has until September 2026 to regain compliance.
-
Capital Needs
The company will need substantial additional funding to complete development of its product candidates. It recently completed a $15 million PIPE financing and amended its loan agreement, but these measures only extend the runway into the second half of 2027.
Analysis · CALC · Life Sciences
CalciMedica's 10-Q reveals a going concern warning — its $18.6 million in cash may not fund operations beyond the second half of 2027. The company is burning cash on clinical trials and has no approved products. While a recent $15 million PIPE and loan amendment bought time, the runway is short. The net loss of $2.7 million for the first half of 2026 was masked by a $7.2 million non-cash gain from warrant and debt fair value adjustments; operating losses remain steep. The stock trades at $0.66, and Nasdaq delisting notices are pending. This filing confirms the company's precarious financial position and the urgent need for additional capital.
How filings like this one have moved
In the 30 days to Oct 16, 2026, 44.9% of the 303 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.26%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CALC was trading at $0.66 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $20.2M. The 52-week trading range was $0.46 to $7.20. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.